The development of drug-device combination products continues to evolve, with increasing attention on how clinical bridging between different delivery systems is handled. In this context, regulatory approaches that support more efficient and scientifically justified development are gaining traction. One example is the molecule-independent device bridging approach (MIDBA), qualified by the European Medicines Agency (EMA). This blog highlights the key implications of this new methodology.
Key regulatory milestone
MIDBA is a methodology qualified by the Committee for Medicinal Products for Human Use (CHMP), designed for clinical bridging from manual subcutaneous injection via a handheld syringe or prefilled syringe to an autoinjector for monoclonal antibodies (mAbs).
It represents a regulatory advancement that supports faster clinical development of drug-device combination products and can contribute to improved patient access to innovative treatments. By providing a defined framework for bridging, MIDBA introduces an alternative to more conventional approaches under specific conditions.
The validity of the MIDBA approach has been demonstrated using the YpsoMate 1 mL and 2.25 mL autoinjectors. This provides a concrete example of how the methodology can be applied and supports its role within a platform-based device strategy.
What MIDBA enables in practice
A central element of MIDBA is its impact on pharmacokinetic (PK) bridging strategies. Traditionally, pivotal trials (Phase III) have often been conducted using manual injections. When an autoinjector is introduced later on, additional PK bridging studies must be performed to demonstrate the clinical comparability of administering the same molecule via two injection methods: manual versus automated.
MIDBA enables an alternative approach by allowing the use of available PK comparability data generated with reference monoclonal antibodies, under defined conditions. This challenges the need for individual PK bridging studies.
In practice, this can streamline clinical development programs and reduce the amount of new clinical evidence required for regulatory submission in the EU. As a result, the overall burden on clinical studies may be reduced, with the potential for shorter development timelines.
Defined conditions for applicability
Certain conditions define the boundaries within which MIDBA can be applied and reflect its basis in scientific consistency.
It applies only to monoclonal antibodies with similar pharmacokinetic and physicochemical properties, ensuring that comparability assumptions remain valid. In addition, several parameters must remain unchanged when bridging from manual to automated injection. These include the use of the same monoclonal antibody, the same dose and formulation, and the same injection volume within a range of 0.5 to 2 mL. The injection site must also remain the same, along with an exposed needle length between 4 and 8 mm.
In addition, the MIDBA approach has been demonstrated using the YpsoMate 1 mL and 2.25 mL autoinjectors. Therefore, the use of alternative autoinjector platforms, or changes to key device-related parameters, requires additional data or scientific justification.
Limitations and important considerations
As with any regulatory approach, the use of MIDBA is subject to important limitations.
Its applicability is shaped by the European regulatory framework in which it was qualified, which may limit how directly it can be applied in other regions. At the same time, MIDBA does not replace existing regulatory requirements. Medicinal products combined with autoinjector devices must still meet all standard expectations for marketing authorization.
In more complex scenarios, such as bridging between different autoinjectors or consolidating multiple smaller injections into a larger volume, the MIDBA baseline may still be considered. However, this requires further justification and will be typically assessed on a case-by-case basis.
Conclusion
MIDBA introduces a qualified and structured approach to clinical device bridging for monoclonal antibodies. By enabling the use of existing PK comparability data under defined conditions, it provides a way to streamline development while maintaining regulatory rigor.
MIDBA reflects a broader shift in regulatory thinking. There is increasing openness to scientifically justified and evidence-based approaches that aim to reduce redundant clinical studies. Rather than lowering regulatory standards, this trend focuses on making more effective use of existing data, provided that the underlying scientific rationale is robust and clearly defined.
Stay tuned, stay informed
Subscribe to the Ypsomed Blog and join our journey to simpler and easier selfcare.
